Shanghai Securities News China Securities Network News -- On January 4, Danish pharmaceutical company Novo Nordisk announced separate research collaborations with Omega Therapeutics and Cellarity, two U.S.-based biotechnology companies, to develop new therapies for cardiometabolic diseases.
Reportedly, Novo Nordisk has partnered with Omega Therapeutics to leverage the company’s platform technology in developing an epigenomic controller aimed at enhancing metabolism, which is part of a potential new approach to obesity management. Meanwhile, the collaboration between the Danish pharmaceutical company and Cellarity will build on prior work, utilizing the company’s platform to develop a small-molecule therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Novo Nordisk stated that these are the first two projects signed under the framework collaboration between Flagship Pioneering and Novo Nordisk. Flagship Pioneering is a biotechnology company dedicated to investing in platforms and creating "world-changing" companies. (Huo Xingyu)